Research ExplorerPublicationsProstate Cancer Molecular Imaging Standardized Evaluation (P...

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Standard

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. / Eiber, M.; Herrmann, K.; Calais, J.; Hadaschik, B.; Giesel, F. L.; Hartenbach, M.; Hope, T.; Reiter, R.; Maurer, T.; Weber, W. A.; Fendler, W. P.

In: J NUCL MED, Vol. 59, No. 3, 2018, p. 469-478.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research

Harvard

Eiber, M, Herrmann, K, Calais, J, Hadaschik, B, Giesel, FL, Hartenbach, M, Hope, T, Reiter, R, Maurer, T, Weber, WA & Fendler, WP 2018, 'Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT', J NUCL MED, vol. 59, no. 3, pp. 469-478. https://doi.org/10.2967/jnumed.117.198119

APA

Eiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., & Fendler, W. P. (2018). Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J NUCL MED, 59(3), 469-478. https://doi.org/10.2967/jnumed.117.198119

Vancouver

Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J NUCL MED. 2018;59(3):469-478. https://doi.org/10.2967/jnumed.117.198119

Bibtex

@article{ba39ece6828345539030adb1ac641085,
title = "Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT",
abstract = "Prostate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.",
keywords = "Promise PSMA-ligand PET/CT criteria interpretation miTNM standardized evaluation",
author = "M. Eiber and K. Herrmann and J. Calais and B. Hadaschik and Giesel, {F. L.} and M. Hartenbach and T. Hope and R. Reiter and T. Maurer and Weber, {W. A.} and Fendler, {W. P.}",
year = "2018",
doi = "10.2967/jnumed.117.198119",
language = "English",
volume = "59",
pages = "469--478",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

AU - Eiber, M.

AU - Herrmann, K.

AU - Calais, J.

AU - Hadaschik, B.

AU - Giesel, F. L.

AU - Hartenbach, M.

AU - Hope, T.

AU - Reiter, R.

AU - Maurer, T.

AU - Weber, W. A.

AU - Fendler, W. P.

PY - 2018

Y1 - 2018

N2 - Prostate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.

AB - Prostate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.

KW - Promise PSMA-ligand PET/CT criteria interpretation miTNM standardized evaluation

U2 - 10.2967/jnumed.117.198119

DO - 10.2967/jnumed.117.198119

M3 - SCORING: Journal article

VL - 59

SP - 469

EP - 478

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 3

ER -